Minster of Health, Professor Isaac Adewole has commended the efforts of the National Agency for Food and Drug Administration and Control (NAFDAC) in staying on course with its regulatory functions, especially the provision of the guidelines which serve as an effective tool in ensuring the safety of regulated products.
He stated this at the Public Presentation of NAFDAC Guidelines for Regulatory Activities (2016) which he said were designed to provide a pathway for global competitiveness for players in pharmaceutical and other healthcare sectors.
His words; “these guidelines place a great emphasis on quality, safety and efficacy. Judicious adherence to the provisions outlined therein will assist our stakeholders compete favourably at the global level and attract foreign earnings to Nigeria in line with the diversification efforts of the current government”
Professor Adewole said in achieving self sufficiency, there is an urgent need to promote local manufacturing of essential medicines for Nigerians, and the eradication of counterfeit drugs. He promised to support policies that will not only assist NAFDAC to effectively carry out its regulatory functions, but also enhance the welfare of the staff of the Agency.
Speaking further, the minister reiterated the need for NAFDAC to continue to work in close collaboration with other health Agencies in the country in order to continuously safeguard the health of the public.
The Minister promised the speedy completion of the accreditation process of NAFDAC drug and vaccine laboratories in Yaba, Lagos by World Health Organization, (WHO) in line with the government‘s resolve to ensure self sufficiency and availability of safe and good quality products for Nigerians, and promote economic diversification.
Earlier, the Acting Director General of NAFDAC, Mrs Yetunde Oni said the scientific nature of the Agency’s operations made it imperative for it to constantly evolve innovative ways that will enhance productivity, aid compliance by stakeholders and make regulatory process seamless between regulators and the regulated.
She said the guidelines provide detailed guidance to assist those handling regulated products to comply with NAFDAC regulations since they spell out details of how the Agency expects regulations to be implemented.
Mrs Oni applauded the collaborative efforts of NAFDAC, WHO, UKaids and PATHS 2 which she said ensured fast and timely completion of the guidelines.
The guidelines include; Good Pharmacovigilance Practice Guidelines 2016, Good Distribution Guidelines for Pharmaceutical Products 2016, Good Manufacturing Practice Guidelines for Pharmaceutical Products 2016, Good Clinical Practice Guidelines 2016 and Good Practices for Pharmaceutical Quality Control Laboratories Guidelines 2016.